Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Vorinostat (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 24 Feb 2014 Biomarkers information updated
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jan 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.